ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2031³â)
Autologous Cell Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
»óǰÄÚµå
:
1539391
¸®¼Ä¡»ç
:
Persistence Market Research
¹ßÇàÀÏ
:
2024³â 08¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 155 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â ÃÖ±Ù ¼¼°è ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ º¸°í¼¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ º¸°í¼´Â ½ÃÀå ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ ¹× °úÁ¦¸¦ Æ÷ÇÔÇÑ ÁÖ¿ä ½ÃÀå ¿ªÇÐÀ» öÀúÈ÷ Æò°¡ÇÏ°í ½ÃÀå ±¸Á¶¿¡ ´ëÇÑ ½ÉÃþÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå ±Ô¸ð(2024E) : 53¾ï ´Þ·¯
¿¹»ó ½ÃÀå ±Ô¸ð(2031F) : 121¾ï ´Þ·¯
¼¼°è ½ÃÀå ¼ºÀå·ü(2024-2031³â CAGR) : 12.6%
ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå - º¸°í¼ ¹üÀ§:
ÀÚ°¡ ¼¼Æ÷ Ä¡·á´Â ȯÀÚ ÀÚ½ÅÀÇ ¼¼Æ÷¸¦ Ä¡·á¿¡ »ç¿ëÇÏ´Â °ÍÀ¸·Î ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ÅðÇ༺ Áúȯ µî ´Ù¾çÇÑ Áúȯ¿¡ Àû¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â Áٱ⼼Æ÷ Ä¡·á, CAR-T ¼¼Æ÷ Ä¡·á, Àç»ýÀÇ·á µî ´Ù¾çÇÑ Ä¡·á¹ýÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ½ÃÀåÀº º´¿ø, Àü¹® Ŭ¸®´Ð, ¿¬±¸±â°üÀ» ´ë»óÀ¸·Î Çϸç, ȯÀÚ °³°³ÀÎÀÇ Çʿ信 µû¶ó ¸ÂÃãÇü Ä¡·á¹ýÀ» Á¦°øÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¼¼Æ÷ Ä¡·á ±â¼úÀÇ ¹ßÀü, ¸¸¼ºÁúȯÀÇ Áõ°¡, »õ·Î¿î Ä¡·á Á¢±Ù¹ý¿¡ ´ëÇÑ ¿¬±¸ È®´ëÀÔ´Ï´Ù.
½ÃÀå ÃËÁø¿äÀÎ:
¼¼°è ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀåÀº ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í º¹ÀâÇÑ Áúº´À» Ä¡·áÇϱâ À§ÇÑ Ã·´Ü ¼¼Æ÷ Ä¡·áÁ¦ äÅÃÀÌ Áõ°¡ÇÏ´Â µî ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ÅðÇ༺ ÁúȯÀÇ ¹ßº´·ü Áõ°¡´Â È¿°úÀûÀ̰í Ç¥ÀûÈµÈ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷ °¡°ø ±â¼úÀÇ Çâ»ó°ú º¸´Ù Á¤±³ÇÑ ¼¼Æ÷ Á¶ÀÛ ¹æ¹ýÀÇ °³¹ß°ú °°Àº ±â¼ú ¹ßÀüÀº ÀÚ°¡ ¼¼Æ÷ Ä¡·áÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í À¯¸®ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¾ïÁ¦¿äÀÎ:
À¯¸ÁÇÑ ¼ºÀå Àü¸Á¿¡µµ ºÒ±¸Çϰí, ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀåÀº ³ôÀº Ä¡·áºñ¿ë, º¹ÀâÇÑ Á¦Á¶ °øÁ¤, ±ÔÁ¦Àû Àå¾Ö¹° µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÚ°¡ ¼¼Æ÷ Ä¡·áÀÇ °³¹ß ¹× »ý»ê¿¡´Â ¸¹Àº ÅõÀÚ¿Í Àü¹® ÀÎÇÁ¶ó°¡ ÇÊ¿äÇϸç, ÀÌ´Â Á¢±Ù¼º°ú °æÁ¦¼ºÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. º¹ÀâÇÑ ±ÔÁ¦¿Í ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇÑ ¾ö°ÝÇÑ ÀÓ»ó½ÃÇèÀÇ Çʿ伺µµ ½ÃÀå È®´ë¿¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÚ°¡ ¼¼Æ÷ Ä¡·á¿¡ ´ëÇÑ Á¦ÇÑµÈ º¸Çè ȯ±Þ ¿É¼Ç°ú Áٱ⼼Æ÷ ¿¬±¸¿Í °ü·ÃµÈ ÀáÀçÀûÀÎ À±¸®Àû ¿ì·Á´Â ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ:
ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀåÀº ±â¼ú Çõ½Å, ÀÀ¿ë ºÐ¾ß È®´ë, ÀÇ·á ¼ºñ½º Á¦°ø ¸ðµ¨ÀÇ ÁøÈ·Î ÀÎÇØ Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀΰøÁö´É, ·Îº¿°øÇÐ µî ÷´Ü ±â¼úÀÌ ¼¼Æ÷ 󸮿¡ ÅëÇÕµÇ¸é¼ Ä¡·áÀÇ Á¤È®¼º°ú È¿À²¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ Àç»ýÀÇ·á¿Í ¸ÂÃãÄ¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå ±â¾÷µé¿¡°Ô »õ·Î¿î ±æÀ» ¿¾îÁÖ°í ÀÖ½À´Ï´Ù. Àü·«Àû ÆÄÆ®³Ê½Ê, ÷´Ü ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ, ºñ¿ë È¿À²ÀûÀÎ Ä¡·á¹ý °³¹ßÀº »õ·Î¿î ±âȸ¸¦ Ȱ¿ëÇÏ°í ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®µé
ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼ °¡Àå ¸¹ÀÌ Ã¤ÅõǴ ÀÚ°¡ ¼¼Æ÷ Ä¡·á´Â ¾î¶² À¯ÇüÀΰ¡?
±â¼úÀÇ ¹ßÀüÀº ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀåÀÇ °æÀï ±¸µµ¸¦ ¾î¶»°Ô º¯È½Ã۰í Àִ°¡?
ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä Ç÷¹À̾î´Â ´©±¸À̸ç, ½ÃÀå °ü·Ã¼ºÀ» À¯ÁöÇϱâ À§ÇØ ¾î¶² Àü·«À» äÅÃÇϰí Àִ°¡?
¼¼°è ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀåÀÇ »õ·Î¿î Æ®·»µå¿Í Àü¸ÁÀº?
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¼ºÀå ¾ïÁ¦¿äÀÎ
±âȸ
°úÁ¦
ÁÖ¿ä µ¿Çâ
°Å½Ã°æÁ¦ ¿äÀÎ
¼¼°èÀÇ ºÎ¹®º° Àü¸Á
¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
¼¼°èÀÇ ÇコÄɾî ÁöÃâ Àü¸Á
COVID-19ÀÇ ¿µÇ⠺м®
¿¹Ãø¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®
Ä¡·á ä¿ë ºÐ¼®
±â¼ú Æò°¡
±ÔÁ¦ »óȲ
¹ë·ùüÀÎ ºÐ¼®
À¯Åë ä³Î/¸¶ÄÏÇ÷¹À̽º ¸®½ºÆ®
ÃÖÁ¾»ç¿ëÀÚ(¾÷°è) ¸®½ºÆ®
ÁÖ¿ä °Å·¡¿Í ÇÕº´
PESTLE ºÐ¼®
Porter's Five Forces ºÐ¼®
Á¦4Àå °¡°Ý µ¿Ç⠺м®, 2019-2031³â
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
Ä¡·áºñ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎ
Ä¡·áº° °¡°Ý ºÐ¼®
Áö¿ªº° °¡°Ý°ú Ä¡·á¹ý ¼±È£
Á¦5Àå ¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ¼ö·® ¿¹Ãø
½ÃÀå ±Ô¸ð(±Ý¾×)¿Í Àü³âºñ ¼ºÀå·ü
Àý´ë ¼öÀÍ ±âȸ
½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®°ú ¿¹Ãø
½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®, 2019-2023³â
½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®°ú ¿¹Ãø, 2024-2031³â
¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : Ä¡·á
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð(±Ý¾×)¿Í ¼ö·® ºÐ¼®, Ä¡·áº°, 2019-2023³â
½ÃÀå ±Ô¸ð(±Ý¾×)¿Í ¼ö·® ºÐ¼®°ú ¿¹Ãø, Ä¡·áº°, 2024-2031³â
ÀÚ°¡ ¼¼Æ÷ ¸é¿ª¿ä¹ý
ÀÚ°¡ Áٱ⼼Æ÷ Ä¡·á
½ÃÀå ¸Å·Â ºÐ¼® : Ä¡·á
¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : ¿ëµµ
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®, ¿ëµµº°, 2019-2023³â
½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®°ú ¿¹Ãø, ¿ëµµº°, 2024-2031³â
¾Ï
½Å°æº¯¼ºÁúȯ
½ÉÇ÷°üÁúȯ
ÀÚ°¡¸é¿ªÁúȯ
Á¤Çü¿Ü°ú
»óó Ä¡À¯
±âŸ
½ÃÀå ¸Å·Â ºÐ¼® : ¿ëµµ
¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : À¯·¡
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®, À¯·¡º°, 2019-2023³â
½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®°ú ¿¹Ãø, À¯·¡º°, 2024-2031³â
°ñ¼ö
Ç¥ÇÇ
Áß°£¿±Áٱ⼼Æ÷
Á¶Ç÷¸ð¼¼Æ÷
¿¬°ñ¼¼Æ÷
±âŸ
½ÃÀå ¸Å·Â ºÐ¼® : À¯·¡
¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : ÃÖÁ¾ ¿ëµµ
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®, ÃÖÁ¾ ¿ëµµº°, 2019-2023³â
½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®°ú ¿¹Ãø, ÃÖÁ¾ ¿ëµµº°, 2024-2031³â
º´¿ø¡¤Å¬¸®´Ð
¿Ü·¡ ¼¾ÅÍ
Çмú°ú ¿¬±¸
±âŸ
½ÃÀå ¸Å·Â ºÐ¼®
Á¦6Àå ¼¼°èÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : Áö¿ª
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð(±Ý¾× ¹× ¼ö·®) ºÐ¼®, 2019-2023³â
½ÃÀå ±Ô¸ð(±Ý¾× ¹× ¼ö·®) ºÐ¼®°ú ¿¹Ãø, 2024-2031³â
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ª
Á¦7Àå ºÏ¹ÌÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦8Àå À¯·´ÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦9Àå µ¿¾Æ½Ã¾ÆÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦10Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦11Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÚ°¡ ¼¼Æ÷ Ä¡·á ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â) ¹× ¿¹Ãø(2024-2031³â)
Á¦13Àå °æÀï »óȲ
½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
½ÃÀå ±¸Á¶
½ÃÀ庰 °æÀï °ÝÈ ¸Ê
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±ÙÀÇ µ¿Çâ)
BrainStorm Cell Therapeutics
Holostem Terapie Avanzate SRL
Pharmicell Co. Inc
Opexa Therapeutics
Lonza
Bristol Myers Squibb
Tego Science
Corning Incorporated
Bio Elpida
Novartis
Autolus therapeutics
Vericel Corporation
Catalent, Inc
Sartorius AG
Á¦14Àå ºÎ·Ï
Á¶»ç ¹æ¹ý
Á¶»ç °¡Á¤
µÎ¹®ÀÚ¾î¿Í ¾à¾î
ksm
¿µ¹® ¸ñÂ÷
Persistence Market Research has recently released a comprehensive report on the worldwide market for autologous cell therapy. The report provides a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market structure.
Key Insights:
Autologous Cell Therapy Market Size (2024E):US$5.3 Bn
Projected Market Value (2031F):US$12.1 Bn
Global Market Growth Rate (CAGR 2024 to 2031): 12.6%
Autologous Cell Therapy Market - Report Scope:
Autologous cell therapy involves using a patient's own cells for treatment, which can be applied to various medical conditions including cancer, autoimmune disorders, and degenerative diseases. This market includes a range of therapies such as stem cell treatments, CAR-T cell therapies, and regenerative medicine. The market caters to hospitals, specialized clinics, and research institutions, offering tailored therapies based on individual patient needs. Market growth is driven by advancements in cell therapy technologies, increasing prevalence of chronic diseases, and expanding research into novel treatment approaches.
Market Growth Drivers:
The global autologous cell therapy market is propelled by several key factors, including rising awareness about personalized medicine and the increasing adoption of advanced cell therapies for treating complex diseases. The growing incidence of cancers, autoimmune disorders, and degenerative conditions fuels demand for effective and targeted treatments. Technological advancements, such as improved cell processing techniques and the development of more sophisticated cell manipulation methods, enhance the efficacy and safety of autologous therapies. Additionally, increasing investments in research and development and favorable regulatory frameworks are further stimulating market growth.
Market Restraints:
Despite promising growth prospects, the autologous cell therapy market faces challenges related to high treatment costs, complex manufacturing processes, and regulatory hurdles. The development and production of autologous therapies require significant investment and specialized infrastructure, which can limit accessibility and affordability. Regulatory complexities and the need for rigorous clinical trials to ensure safety and efficacy also pose barriers to market expansion. Furthermore, limited reimbursement options for autologous therapies and potential ethical concerns related to stem cell research can impact market growth.
Market Opportunities:
The autologous cell therapy market presents significant growth opportunities driven by technological innovations, expanding applications, and evolving healthcare delivery models. The integration of advanced technologies, such as artificial intelligence and robotics in cell processing, is enhancing treatment precision and efficiency. The increasing focus on regenerative medicine and personalized treatments for various conditions opens new avenues for market players. Strategic partnerships, investment in cutting-edge research, and the development of cost-effective therapies are essential to capitalize on emerging opportunities and drive market growth.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the autologous cell therapy market globally?
Which types of autologous cell therapies are seeing the most adoption across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the autologous cell therapy market?
Who are the key players contributing to the autologous cell therapy market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global autologous cell therapy market?
Competitive Intelligence and Business Strategy:
Leading players in the global autologous cell therapy market, including Novartis AG, Gilead Sciences, Inc., and Kite Pharma, Inc., focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced cell therapies, such as CAR-T and stem cell-based treatments, catering to diverse therapeutic needs. Collaborations with research institutions, healthcare providers, and regulatory agencies facilitate market access and promote technology adoption. Emphasis on clinical research, evidence-based practice, and patient-centered approaches is crucial to sustaining market leadership in the rapidly evolving autologous cell therapy landscape.
Key Companies Profiled:
BrainStorm Cell Therapeutics
Holostem Terapie Avanzate S.R.L
Pharmicell Co. Inc
Opexa Therapeutics
Lonza
Bristol Myers Squibb
Tego Science
Corning Incorporated
Bio Elpida
Novartis
Autolus therapeutics
Vericel Corporation
Catalent, Inc
Sartorius AG
Caladrius Biosciences Inc
U.S. Stem Cell Inc
Autologous Cell Therapy Industry Segmentation
By Therapy
Autologous Cellular Immunotherapies
Autologous Stem Cell Therapy
By Application
Cancer
Neurodegenerative disorders
Cardiovascular disorders
Autoimmune disorders
Orthopedics
Wound healing
By Source
Bone Marrow
Epidermis
Mesenchymal stem cells
Haematopoietic stem cells
Chondrocytes
By End-use
Hospitals & Clinics
Ambulatory Centers
Academics & Research
By Geographical Regions
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Autologous Cell Therapy Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Therapy Adoption Analysis
3.2. Technology Assessment
3.3. Regulatory Landscape
3.4. Value Chain Analysis
3.4.1. List of Distribution Channel/Marketplaces
3.4.1.1. Retail
3.4.1.2. Audiology
3.4.1.3. E-Commerce
3.4.2. List of End User (Industry)
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis
4. Price Trend Analysis, 2019-2031
4.1. Key Highlights
4.2. Key Factors Impacting Therapy Prices
4.3. Pricing Analysis, By Therapy
4.4. Regional Prices and Therapy Preferences
5. Global Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
5.1. Key Highlights
5.1.1. Market Volume (Units) Projections
5.1.2. Market Size (US$ Bn) and Y-o-Y Growth
5.1.3. Absolute $ Opportunity
5.2. Market Size (US$ Bn) Analysis and Forecast
5.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
5.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
5.3. Global Autologous Cell Therapy Market Outlook: Therapy
5.3.1. Introduction / Key Findings
5.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Therapy, 2019-2023
5.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
5.3.3.1. Autologous Cellular Immunotherapies
5.3.3.2. Autologous Stem Cell Therapy
5.4. Market Attractiveness Analysis: Therapy
5.5. Global Autologous Cell Therapy Market Outlook: Application
5.5.1. Introduction / Key Findings
5.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2023
5.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
5.5.3.1. Cancer
5.5.3.2. Neurodegenerative disorders
5.5.3.3. Cardiovascular disorders
5.5.3.4. Autoimmune disorders
5.5.3.5. Orthopedics
5.5.3.6. Wound healing
5.5.3.7. Others
5.6. Market Attractiveness Analysis: Application
5.7. Global Autologous Cell Therapy Market Outlook: Source
5.7.1. Introduction / Key Findings
5.7.2. Historical Market Size (US$ Bn) Analysis, By Source, 2019-2023
5.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
5.7.3.1. Bone Marrow
5.7.3.2. Epidermis
5.7.3.3. Mesenchymal stem cells
5.7.3.4. Haematopoietic stem cells
5.7.3.5. Chondrocytes
5.7.3.6. Others
5.8. Market Attractiveness Analysis: Source Global Autologous Cell Therapy Market Outlook: End Use
5.8.1. Introduction / Key Findings
5.8.2. Historical Market Size (US$ Bn) Analysis, By End Use, 2019-2023
5.8.3. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
5.8.3.1. Hospitals & Clinics
5.8.3.2. Ambulatory Centers
5.8.3.3. Academics & Research
5.8.3.4. Others
5.9. Market Attractiveness Analysis: Source
6. Global Autologous Cell Therapy Market Outlook: Region
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019-2023
6.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2024-2031
6.3.1. North America
6.3.2. Europe
6.3.3. East Asia
6.3.4. South Asia and Oceania
6.3.5. Latin America
6.3.6. Middle East & Africa
6.4. Market Attractiveness Analysis: Region
7. North America Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
7.3.1. By Country
7.3.2. By Therapy
7.3.3. By Application
7.3.4. By Source
7.3.5. By End Use
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
7.4.1. U.S.
7.4.2. Canada
7.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
7.5.1. Autologous Cellular Immunotherapies
7.5.2. Autologous Stem Cell Therapy
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
7.6.1. Cancer
7.6.2. Neurodegenerative disorders
7.6.3. Cardiovascular disorders
7.6.4. Autoimmune disorders
7.6.5. Orthopedics
7.6.6. Wound healing
7.6.7. Others
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
7.7.1. Bone Marrow
7.7.2. Epidermis
7.7.3. Mesenchymal stem cells
7.7.4. Haematopoietic stem cells
7.7.5. Chondrocytes
7.7.6. Others
7.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
7.8.1. Hospitals & Clinics
7.8.2. Ambulatory Centers
7.8.3. Academics & Research
7.8.4. Others
7.9. Market Attractiveness Analysis
8. Europe Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
8.3.1. By Country
8.3.2. By Therapy
8.3.3. By Application
8.3.4. By Source
8.3.5. By End Use
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
8.4.1. Germany
8.4.2. France
8.4.3. U.K.
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Turkey
8.4.8. Rest of Europe
8.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
8.5.1. Autologous Cellular Immunotherapies
8.5.2. Autologous Stem Cell Therapy
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
8.6.1. Cancer
8.6.2. Neurodegenerative disorders
8.6.3. Cardiovascular disorders
8.6.4. Autoimmune disorders
8.6.5. Orthopedics
8.6.6. Wound healing
8.6.7. Others
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
8.7.1. Bone Marrow
8.7.2. Epidermis
8.7.3. Mesenchymal stem cells
8.7.4. Haematopoietic stem cells
8.7.5. Chondrocytes
8.7.6. Others
8.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
8.8.1. Hospitals & Clinics
8.8.2. Ambulatory Centers
8.8.3. Academics & Research
8.8.4. Others
8.9. Market Attractiveness Analysis
9. East Asia Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
9.3.1. By Country
9.3.2. By Therapy
9.3.3. By Application
9.3.4. By Source
9.3.5. By End Use
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
9.4.1. China
9.4.2. Japan
9.4.3. South Korea
9.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
9.5.1. Autologous Cellular Immunotherapies
9.5.2. Autologous Stem Cell Therapy
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
9.6.1. Cancer
9.6.2. Neurodegenerative disorders
9.6.3. Cardiovascular disorders
9.6.4. Autoimmune disorders
9.6.5. Orthopedics
9.6.6. Wound healing
9.6.7. Others
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
9.7.1. Bone Marrow
9.7.2. Epidermis
9.7.3. Mesenchymal stem cells
9.7.4. Haematopoietic stem cells
9.7.5. Chondrocytes
9.7.6. Others
9.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
9.8.1. Hospitals & Clinics
9.8.2. Ambulatory Centers
9.8.3. Academics & Research
9.8.4. Others
9.9. Market Attractiveness Analysis
10. South Asia & Oceania Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
10.3.1. By Country
10.3.2. By Therapy
10.3.3. By Application
10.3.4. By Source
10.3.5. By End Use
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
10.4.1. India
10.4.2. Southeast Asia
10.4.3. ANZ
10.4.4. Rest of South Asia & Oceania
10.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
10.5.1. Autologous Cellular Immunotherapies
10.5.2. Autologous Stem Cell Therapy
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
10.6.1. Cancer
10.6.2. Neurodegenerative disorders
10.6.3. Cardiovascular disorders
10.6.4. Autoimmune disorders
10.6.5. Orthopedics
10.6.6. Wound healing
10.6.7. Others
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
10.7.1. Bone Marrow
10.7.2. Epidermis
10.7.3. Mesenchymal stem cells
10.7.4. Haematopoietic stem cells
10.7.5. Chondrocytes
10.7.6. Others
10.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
10.8.1. Hospitals & Clinics
10.8.2. Ambulatory Centers
10.8.3. Academics & Research
10.8.4. Others
10.9. Market Attractiveness Analysis
11. Latin America Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
11.1. Key Highlights
11.2. Pricing Analysis
11.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
11.3.1. By Country
11.3.2. By Therapy
11.3.3. By Application
11.3.4. By Source
11.3.5. By End Use
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
11.5.1. Autologous Cellular Immunotherapies
11.5.2. Autologous Stem Cell Therapy
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
11.6.1. Cancer
11.6.2. Neurodegenerative disorders
11.6.3. Cardiovascular disorders
11.6.4. Autoimmune disorders
11.6.5. Orthopedics
11.6.6. Wound healing
11.6.7. Others
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
11.7.1. Bone Marrow
11.7.2. Epidermis
11.7.3. Mesenchymal stem cells
11.7.4. Haematopoietic stem cells
11.7.5. Chondrocytes
11.7.6. Others
11.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
11.8.1. Hospitals & Clinics
11.8.2. Ambulatory Centers
11.8.3. Academics & Research
11.8.4. Others
11.9. Market Attractiveness Analysis
12. Middle East & Africa Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
12.1. Key Highlights
12.2. Pricing Analysis
12.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
12.3.1. By Country
12.3.2. By Therapy
12.3.3. By Application
12.3.4. By Source
12.3.5. By End Use
12.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
12.4.1. GCC Countries
12.4.2. Egypt
12.4.3. South Africa
12.4.4. Northern Africa
12.4.5. Rest of Middle East & Africa
12.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
12.5.1. Autologous Cellular Immunotherapies
12.5.2. Autologous Stem Cell Therapy
12.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
12.6.1. Cancer
12.6.2. Neurodegenerative disorders
12.6.3. Cardiovascular disorders
12.6.4. Autoimmune disorders
12.6.5. Orthopedics
12.6.6. Wound healing
12.6.7. Others
12.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
12.7.1. Bone Marrow
12.7.2. Epidermis
12.7.3. Mesenchymal stem cells
12.7.4. Haematopoietic stem cells
12.7.5. Chondrocytes
12.7.6. Others
12.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
12.8.1. Hospitals & Clinics
12.8.2. Ambulatory Centers
12.8.3. Academics & Research
12.8.4. Others
12.9. Market Attractiveness Analysis
13. Competition Landscape
13.1. Market Share Analysis, 2024
13.2. Market Structure
13.2.1. Competition Intensity Mapping By Market
13.2.2. Competition Dashboard
13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
13.3.1. BrainStorm Cell Therapeutics
13.3.1.1. Overview
13.3.1.2. Segments and Therapys
13.3.1.3. Key Financials
13.3.1.4. Market Developments
13.3.1.5. Market Strategy
13.3.2. Holostem Terapie Avanzate S.R.L
13.3.3. Pharmicell Co. Inc
13.3.4. Opexa Therapeutics
13.3.5. Lonza
13.3.6. Bristol Myers Squibb
13.3.7. Tego Science
13.3.8. Corning Incorporated
13.3.9. Bio Elpida
13.3.10. Novartis
13.3.11. Autolus therapeutics
13.3.12. Vericel Corporation
13.3.13. Catalent, Inc
13.3.14. Sartorius AG
14. Appendix
14.1. Research Methodology
14.2. Research Assumptions
14.3. Acronyms and Abbreviations
°ü·ÃÀÚ·á